nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—kidney cancer	0.445	1	CbGaD
Clodronate—SLC25A6—renal system—kidney cancer	0.00797	0.0775	CbGeAlD
Clodronate—SLC25A6—kidney—kidney cancer	0.0077	0.075	CbGeAlD
Clodronate—SLC25A5—nephron tubule—kidney cancer	0.00762	0.0742	CbGeAlD
Clodronate—SLC25A6—gonad—kidney cancer	0.00714	0.0695	CbGeAlD
Clodronate—SLC25A5—renal system—kidney cancer	0.00693	0.0674	CbGeAlD
Clodronate—SLC25A5—kidney—kidney cancer	0.0067	0.0652	CbGeAlD
Clodronate—PTGS2—nephron—kidney cancer	0.00665	0.0647	CbGeAlD
Clodronate—SLC25A5—cortex of kidney—kidney cancer	0.00652	0.0635	CbGeAlD
Clodronate—SLC25A4—renal system—kidney cancer	0.00649	0.0632	CbGeAlD
Clodronate—SLC25A4—kidney—kidney cancer	0.00628	0.0611	CbGeAlD
Clodronate—SLC25A5—gonad—kidney cancer	0.00621	0.0605	CbGeAlD
Clodronate—SLC25A5—cardiac atrium—kidney cancer	0.00621	0.0604	CbGeAlD
Clodronate—SLC25A4—cortex of kidney—kidney cancer	0.00611	0.0595	CbGeAlD
Clodronate—SLC25A4—gonad—kidney cancer	0.00582	0.0567	CbGeAlD
Clodronate—SLC25A4—cardiac atrium—kidney cancer	0.00582	0.0566	CbGeAlD
Clodronate—SLC25A6—Vinorelbine—Vincristine—kidney cancer	0.00297	0.37	CbGdCrCtD
Clodronate—SLC25A6—Vinorelbine—Vinblastine—kidney cancer	0.00297	0.37	CbGdCrCtD
Clodronate—Zoledronate—CA2—kidney cancer	0.0025	1	CrCbGaD
Clodronate—SLC25A5—Azacitidine—Gemcitabine—kidney cancer	0.00209	0.26	CbGdCrCtD
Clodronate—PTGS2—renal system—kidney cancer	0.0013	0.0127	CbGeAlD
Clodronate—PTGS2—kidney—kidney cancer	0.00126	0.0123	CbGeAlD
Clodronate—Decreased appetite—Temsirolimus—kidney cancer	0.000509	0.00179	CcSEcCtD
Clodronate—Urinary tract disorder—Sunitinib—kidney cancer	0.000506	0.00177	CcSEcCtD
Clodronate—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000506	0.00177	CcSEcCtD
Clodronate—Bronchospasm—Gemcitabine—kidney cancer	0.000505	0.00177	CcSEcCtD
Clodronate—Connective tissue disorder—Sunitinib—kidney cancer	0.000503	0.00177	CcSEcCtD
Clodronate—Urethral disorder—Sunitinib—kidney cancer	0.000502	0.00176	CcSEcCtD
Clodronate—Anaemia—Vinblastine—kidney cancer	0.000495	0.00174	CcSEcCtD
Clodronate—Anaemia—Everolimus—kidney cancer	0.000493	0.00173	CcSEcCtD
Clodronate—Dyspnoea—Pazopanib—kidney cancer	0.000492	0.00173	CcSEcCtD
Clodronate—Angioedema—Everolimus—kidney cancer	0.000488	0.00171	CcSEcCtD
Clodronate—Dyspepsia—Pazopanib—kidney cancer	0.000486	0.0017	CcSEcCtD
Clodronate—Pneumonia—Vincristine—kidney cancer	0.000485	0.0017	CcSEcCtD
Clodronate—Pharyngitis—Dactinomycin—kidney cancer	0.000481	0.00169	CcSEcCtD
Clodronate—Mediastinal disorder—Sorafenib—kidney cancer	0.00048	0.00168	CcSEcCtD
Clodronate—Decreased appetite—Pazopanib—kidney cancer	0.00048	0.00168	CcSEcCtD
Clodronate—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000476	0.00167	CcSEcCtD
Clodronate—Hepatic function abnormal—Capecitabine—kidney cancer	0.000467	0.00164	CcSEcCtD
Clodronate—Blood creatinine increased—Paclitaxel—kidney cancer	0.000466	0.00163	CcSEcCtD
Clodronate—Abdominal pain—Temsirolimus—kidney cancer	0.000463	0.00162	CcSEcCtD
Clodronate—Dehydration—Paclitaxel—kidney cancer	0.000462	0.00162	CcSEcCtD
Clodronate—Mediastinal disorder—Sunitinib—kidney cancer	0.000462	0.00162	CcSEcCtD
Clodronate—Pneumonia—Gemcitabine—kidney cancer	0.00046	0.00161	CcSEcCtD
Clodronate—Abdominal pain upper—Paclitaxel—kidney cancer	0.000454	0.00159	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000451	0.00158	CcSEcCtD
Clodronate—Renal failure—Gemcitabine—kidney cancer	0.00045	0.00158	CcSEcCtD
Clodronate—Renal failure acute—Capecitabine—kidney cancer	0.000442	0.00155	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Paclitaxel—kidney cancer	0.000439	0.00154	CcSEcCtD
Clodronate—Abdominal pain—Pazopanib—kidney cancer	0.000436	0.00153	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000435	0.00153	CcSEcCtD
Clodronate—Infection—Everolimus—kidney cancer	0.000433	0.00152	CcSEcCtD
Clodronate—Dysphagia—Paclitaxel—kidney cancer	0.00043	0.00151	CcSEcCtD
Clodronate—Renal impairment—Capecitabine—kidney cancer	0.000429	0.0015	CcSEcCtD
Clodronate—Anaemia—Sorafenib—kidney cancer	0.000428	0.0015	CcSEcCtD
Clodronate—Urinary tract disorder—Vincristine—kidney cancer	0.000428	0.0015	CcSEcCtD
Clodronate—Connective tissue disorder—Vincristine—kidney cancer	0.000426	0.00149	CcSEcCtD
Clodronate—Urethral disorder—Vincristine—kidney cancer	0.000425	0.00149	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—kidney cancer	0.000424	0.00149	CcSEcCtD
Clodronate—Angioedema—Sorafenib—kidney cancer	0.000423	0.00148	CcSEcCtD
Clodronate—Skin disorder—Everolimus—kidney cancer	0.000423	0.00148	CcSEcCtD
Clodronate—Cardiac failure—Capecitabine—kidney cancer	0.000418	0.00147	CcSEcCtD
Clodronate—Infection—Erlotinib—kidney cancer	0.000418	0.00146	CcSEcCtD
Clodronate—Anorexia—Vinblastine—kidney cancer	0.000417	0.00146	CcSEcCtD
Clodronate—Extravasation—Doxorubicin—kidney cancer	0.000415	0.00146	CcSEcCtD
Clodronate—Anorexia—Everolimus—kidney cancer	0.000415	0.00146	CcSEcCtD
Clodronate—Pruritus—Temsirolimus—kidney cancer	0.000414	0.00145	CcSEcCtD
Clodronate—Anaemia—Sunitinib—kidney cancer	0.000412	0.00145	CcSEcCtD
Clodronate—Skin disorder—Erlotinib—kidney cancer	0.000408	0.00143	CcSEcCtD
Clodronate—Pharyngitis—Gemcitabine—kidney cancer	0.000408	0.00143	CcSEcCtD
Clodronate—Angioedema—Sunitinib—kidney cancer	0.000407	0.00143	CcSEcCtD
Clodronate—Urinary tract disorder—Gemcitabine—kidney cancer	0.000406	0.00142	CcSEcCtD
Clodronate—Connective tissue disorder—Gemcitabine—kidney cancer	0.000404	0.00142	CcSEcCtD
Clodronate—Urethral disorder—Gemcitabine—kidney cancer	0.000403	0.00141	CcSEcCtD
Clodronate—Diarrhoea—Temsirolimus—kidney cancer	0.000401	0.00141	CcSEcCtD
Clodronate—Anorexia—Erlotinib—kidney cancer	0.000401	0.00141	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—kidney cancer	0.000396	0.00139	CcSEcCtD
Clodronate—Oliguria—Doxorubicin—kidney cancer	0.000393	0.00138	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000392	0.00137	CcSEcCtD
Clodronate—Mediastinal disorder—Vincristine—kidney cancer	0.00039	0.00137	CcSEcCtD
Clodronate—Pruritus—Pazopanib—kidney cancer	0.00039	0.00137	CcSEcCtD
Clodronate—Anaemia—Dactinomycin—kidney cancer	0.00039	0.00137	CcSEcCtD
Clodronate—Dyspnoea—Everolimus—kidney cancer	0.000388	0.00136	CcSEcCtD
Clodronate—Pneumonia—Paclitaxel—kidney cancer	0.000385	0.00135	CcSEcCtD
Clodronate—Dyspepsia—Everolimus—kidney cancer	0.000383	0.00135	CcSEcCtD
Clodronate—Blood creatinine increased—Capecitabine—kidney cancer	0.000382	0.00134	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—kidney cancer	0.000381	0.00134	CcSEcCtD
Clodronate—Decreased appetite—Vinblastine—kidney cancer	0.00038	0.00133	CcSEcCtD
Clodronate—Dehydration—Capecitabine—kidney cancer	0.00038	0.00133	CcSEcCtD
Clodronate—Decreased appetite—Everolimus—kidney cancer	0.000379	0.00133	CcSEcCtD
Clodronate—Diarrhoea—Pazopanib—kidney cancer	0.000377	0.00132	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000377	0.00132	CcSEcCtD
Clodronate—Renal failure—Paclitaxel—kidney cancer	0.000377	0.00132	CcSEcCtD
Clodronate—Gastrointestinal disorder—Everolimus—kidney cancer	0.000376	0.00132	CcSEcCtD
Clodronate—Infection—Sorafenib—kidney cancer	0.000376	0.00132	CcSEcCtD
Clodronate—Dyspnoea—Erlotinib—kidney cancer	0.000375	0.00131	CcSEcCtD
Clodronate—Abdominal pain upper—Capecitabine—kidney cancer	0.000373	0.00131	CcSEcCtD
Clodronate—Vomiting—Temsirolimus—kidney cancer	0.000372	0.00131	CcSEcCtD
Clodronate—Mediastinal disorder—Gemcitabine—kidney cancer	0.00037	0.0013	CcSEcCtD
Clodronate—Dyspepsia—Erlotinib—kidney cancer	0.00037	0.0013	CcSEcCtD
Clodronate—Rash—Temsirolimus—kidney cancer	0.000369	0.0013	CcSEcCtD
Clodronate—Dermatitis—Temsirolimus—kidney cancer	0.000369	0.00129	CcSEcCtD
Clodronate—Skin disorder—Sorafenib—kidney cancer	0.000367	0.00129	CcSEcCtD
Clodronate—Decreased appetite—Erlotinib—kidney cancer	0.000365	0.00128	CcSEcCtD
Clodronate—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000363	0.00127	CcSEcCtD
Clodronate—Hepatocellular injury—Doxorubicin—kidney cancer	0.000362	0.00127	CcSEcCtD
Clodronate—Infection—Sunitinib—kidney cancer	0.000361	0.00127	CcSEcCtD
Clodronate—Anorexia—Sorafenib—kidney cancer	0.00036	0.00126	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Capecitabine—kidney cancer	0.00036	0.00126	CcSEcCtD
Clodronate—Skin disorder—Sunitinib—kidney cancer	0.000353	0.00124	CcSEcCtD
Clodronate—Dysphagia—Capecitabine—kidney cancer	0.000353	0.00124	CcSEcCtD
Clodronate—Vomiting—Pazopanib—kidney cancer	0.000351	0.00123	CcSEcCtD
Clodronate—Anaemia—Vincristine—kidney cancer	0.000348	0.00122	CcSEcCtD
Clodronate—Rash—Pazopanib—kidney cancer	0.000348	0.00122	CcSEcCtD
Clodronate—Nausea—Temsirolimus—kidney cancer	0.000348	0.00122	CcSEcCtD
Clodronate—Dermatitis—Pazopanib—kidney cancer	0.000348	0.00122	CcSEcCtD
Clodronate—Bronchospasm—Capecitabine—kidney cancer	0.000347	0.00122	CcSEcCtD
Clodronate—Anorexia—Sunitinib—kidney cancer	0.000347	0.00122	CcSEcCtD
Clodronate—Abdominal pain—Vinblastine—kidney cancer	0.000346	0.00121	CcSEcCtD
Clodronate—Abdominal pain—Everolimus—kidney cancer	0.000344	0.00121	CcSEcCtD
Clodronate—Infection—Dactinomycin—kidney cancer	0.000342	0.0012	CcSEcCtD
Clodronate—Pharyngitis—Paclitaxel—kidney cancer	0.000341	0.0012	CcSEcCtD
Clodronate—Urinary tract disorder—Paclitaxel—kidney cancer	0.00034	0.00119	CcSEcCtD
Clodronate—Connective tissue disorder—Paclitaxel—kidney cancer	0.000338	0.00119	CcSEcCtD
Clodronate—Urethral disorder—Paclitaxel—kidney cancer	0.000337	0.00118	CcSEcCtD
Clodronate—Dyspnoea—Sorafenib—kidney cancer	0.000337	0.00118	CcSEcCtD
Clodronate—Dyspepsia—Sorafenib—kidney cancer	0.000333	0.00117	CcSEcCtD
Clodronate—Abdominal pain—Erlotinib—kidney cancer	0.000332	0.00117	CcSEcCtD
Clodronate—Anaemia—Gemcitabine—kidney cancer	0.000331	0.00116	CcSEcCtD
Clodronate—Decreased appetite—Sorafenib—kidney cancer	0.000329	0.00115	CcSEcCtD
Clodronate—Anorexia—Dactinomycin—kidney cancer	0.000328	0.00115	CcSEcCtD
Clodronate—Nausea—Pazopanib—kidney cancer	0.000328	0.00115	CcSEcCtD
Clodronate—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000326	0.00115	CcSEcCtD
Clodronate—Dyspnoea—Sunitinib—kidney cancer	0.000324	0.00114	CcSEcCtD
Clodronate—Dyspepsia—Sunitinib—kidney cancer	0.00032	0.00112	CcSEcCtD
Clodronate—Pneumonia—Capecitabine—kidney cancer	0.000316	0.00111	CcSEcCtD
Clodronate—Decreased appetite—Sunitinib—kidney cancer	0.000316	0.00111	CcSEcCtD
Clodronate—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000314	0.0011	CcSEcCtD
Clodronate—Mediastinal disorder—Paclitaxel—kidney cancer	0.00031	0.00109	CcSEcCtD
Clodronate—Renal failure—Capecitabine—kidney cancer	0.000309	0.00108	CcSEcCtD
Clodronate—Pruritus—Everolimus—kidney cancer	0.000308	0.00108	CcSEcCtD
Clodronate—Infection—Vincristine—kidney cancer	0.000306	0.00107	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000302	0.00106	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000301	0.00106	CcSEcCtD
Clodronate—Urticaria—Sorafenib—kidney cancer	0.0003	0.00105	CcSEcCtD
Clodronate—Decreased appetite—Dactinomycin—kidney cancer	0.000299	0.00105	CcSEcCtD
Clodronate—Diarrhoea—Vinblastine—kidney cancer	0.000299	0.00105	CcSEcCtD
Clodronate—Abdominal pain—Sorafenib—kidney cancer	0.000299	0.00105	CcSEcCtD
Clodronate—Diarrhoea—Everolimus—kidney cancer	0.000298	0.00105	CcSEcCtD
Clodronate—Pruritus—Erlotinib—kidney cancer	0.000297	0.00104	CcSEcCtD
Clodronate—Anorexia—Vincristine—kidney cancer	0.000293	0.00103	CcSEcCtD
Clodronate—Infection—Gemcitabine—kidney cancer	0.00029	0.00102	CcSEcCtD
Clodronate—Abdominal pain—Sunitinib—kidney cancer	0.000288	0.00101	CcSEcCtD
Clodronate—Diarrhoea—Erlotinib—kidney cancer	0.000288	0.00101	CcSEcCtD
Clodronate—Renal failure acute—Doxorubicin—kidney cancer	0.000285	0.001	CcSEcCtD
Clodronate—Skin disorder—Gemcitabine—kidney cancer	0.000284	0.000995	CcSEcCtD
Clodronate—Pharyngitis—Capecitabine—kidney cancer	0.00028	0.000983	CcSEcCtD
Clodronate—Urinary tract disorder—Capecitabine—kidney cancer	0.000279	0.000978	CcSEcCtD
Clodronate—Anorexia—Gemcitabine—kidney cancer	0.000278	0.000976	CcSEcCtD
Clodronate—Vomiting—Vinblastine—kidney cancer	0.000278	0.000975	CcSEcCtD
Clodronate—Connective tissue disorder—Capecitabine—kidney cancer	0.000277	0.000973	CcSEcCtD
Clodronate—Vomiting—Everolimus—kidney cancer	0.000277	0.000972	CcSEcCtD
Clodronate—Anaemia—Paclitaxel—kidney cancer	0.000277	0.000971	CcSEcCtD
Clodronate—Urethral disorder—Capecitabine—kidney cancer	0.000277	0.000971	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—kidney cancer	0.000276	0.00097	CcSEcCtD
Clodronate—Rash—Everolimus—kidney cancer	0.000275	0.000963	CcSEcCtD
Clodronate—Dermatitis—Everolimus—kidney cancer	0.000274	0.000963	CcSEcCtD
Clodronate—Angioedema—Paclitaxel—kidney cancer	0.000274	0.00096	CcSEcCtD
Clodronate—Abdominal pain—Dactinomycin—kidney cancer	0.000272	0.000955	CcSEcCtD
Clodronate—Cardiac failure—Doxorubicin—kidney cancer	0.00027	0.000946	CcSEcCtD
Clodronate—Decreased appetite—Vincristine—kidney cancer	0.000268	0.000938	CcSEcCtD
Clodronate—Pruritus—Sorafenib—kidney cancer	0.000268	0.000938	CcSEcCtD
Clodronate—Vomiting—Erlotinib—kidney cancer	0.000267	0.000937	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vincristine—kidney cancer	0.000266	0.000932	CcSEcCtD
Clodronate—Rash—Erlotinib—kidney cancer	0.000265	0.00093	CcSEcCtD
Clodronate—Dermatitis—Erlotinib—kidney cancer	0.000265	0.000929	CcSEcCtD
Clodronate—Dyspnoea—Gemcitabine—kidney cancer	0.00026	0.000913	CcSEcCtD
Clodronate—Nausea—Vinblastine—kidney cancer	0.00026	0.000911	CcSEcCtD
Clodronate—Nausea—Everolimus—kidney cancer	0.000259	0.000908	CcSEcCtD
Clodronate—Diarrhoea—Sorafenib—kidney cancer	0.000259	0.000907	CcSEcCtD
Clodronate—Pruritus—Sunitinib—kidney cancer	0.000257	0.000903	CcSEcCtD
Clodronate—Mediastinal disorder—Capecitabine—kidney cancer	0.000254	0.000893	CcSEcCtD
Clodronate—Decreased appetite—Gemcitabine—kidney cancer	0.000254	0.00089	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000253	0.000888	CcSEcCtD
Clodronate—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000252	0.000884	CcSEcCtD
Clodronate—Nausea—Erlotinib—kidney cancer	0.00025	0.000876	CcSEcCtD
Clodronate—Diarrhoea—Sunitinib—kidney cancer	0.000249	0.000873	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—kidney cancer	0.000246	0.000864	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—kidney cancer	0.000245	0.000858	CcSEcCtD
Clodronate—Abdominal pain—Vincristine—kidney cancer	0.000243	0.000853	CcSEcCtD
Clodronate—Infection—Paclitaxel—kidney cancer	0.000243	0.000852	CcSEcCtD
Clodronate—Vomiting—Sorafenib—kidney cancer	0.00024	0.000843	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—kidney cancer	0.00024	0.000843	CcSEcCtD
Clodronate—Rash—Sorafenib—kidney cancer	0.000238	0.000836	CcSEcCtD
Clodronate—Dermatitis—Sorafenib—kidney cancer	0.000238	0.000836	CcSEcCtD
Clodronate—Skin disorder—Paclitaxel—kidney cancer	0.000237	0.000833	CcSEcCtD
Clodronate—Diarrhoea—Dactinomycin—kidney cancer	0.000236	0.000827	CcSEcCtD
Clodronate—Anorexia—Paclitaxel—kidney cancer	0.000233	0.000817	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000232	0.000814	CcSEcCtD
Clodronate—Vomiting—Sunitinib—kidney cancer	0.000231	0.000811	CcSEcCtD
Clodronate—Rash—Sunitinib—kidney cancer	0.000229	0.000805	CcSEcCtD
Clodronate—Dermatitis—Sunitinib—kidney cancer	0.000229	0.000804	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—kidney cancer	0.000227	0.000798	CcSEcCtD
Clodronate—Anaemia—Capecitabine—kidney cancer	0.000227	0.000797	CcSEcCtD
Clodronate—Nausea—Sorafenib—kidney cancer	0.000225	0.000788	CcSEcCtD
Clodronate—Vomiting—Dactinomycin—kidney cancer	0.000219	0.000768	CcSEcCtD
Clodronate—Dyspnoea—Paclitaxel—kidney cancer	0.000218	0.000764	CcSEcCtD
Clodronate—Rash—Dactinomycin—kidney cancer	0.000217	0.000762	CcSEcCtD
Clodronate—Nausea—Sunitinib—kidney cancer	0.000216	0.000758	CcSEcCtD
Clodronate—Dyspepsia—Paclitaxel—kidney cancer	0.000215	0.000755	CcSEcCtD
Clodronate—Decreased appetite—Paclitaxel—kidney cancer	0.000212	0.000745	CcSEcCtD
Clodronate—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000211	0.00074	CcSEcCtD
Clodronate—Diarrhoea—Vincristine—kidney cancer	0.000211	0.000739	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000208	0.000729	CcSEcCtD
Clodronate—Pruritus—Gemcitabine—kidney cancer	0.000207	0.000725	CcSEcCtD
Clodronate—Nausea—Dactinomycin—kidney cancer	0.000205	0.000718	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—kidney cancer	0.000204	0.000715	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—ANXA1—kidney cancer	0.000202	0.00129	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS1—kidney cancer	0.000201	0.00128	CbGpPWpGaD
Clodronate—Diarrhoea—Gemcitabine—kidney cancer	0.0002	0.000701	CcSEcCtD
Clodronate—Renal failure—Doxorubicin—kidney cancer	0.000199	0.000699	CcSEcCtD
Clodronate—Infection—Capecitabine—kidney cancer	0.000199	0.000699	CcSEcCtD
Clodronate—SLC25A6—Disease—PSMD7—kidney cancer	0.000197	0.00126	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PSMD7—kidney cancer	0.000197	0.00126	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ITPR2—kidney cancer	0.000197	0.00126	CbGpPWpGaD
Clodronate—Vomiting—Vincristine—kidney cancer	0.000196	0.000686	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CA9—kidney cancer	0.000195	0.00124	CbGpPWpGaD
Clodronate—Skin disorder—Capecitabine—kidney cancer	0.000195	0.000683	CcSEcCtD
Clodronate—Urticaria—Paclitaxel—kidney cancer	0.000194	0.000681	CcSEcCtD
Clodronate—Rash—Vincristine—kidney cancer	0.000194	0.000681	CcSEcCtD
Clodronate—Dermatitis—Vincristine—kidney cancer	0.000194	0.00068	CcSEcCtD
Clodronate—Abdominal pain—Paclitaxel—kidney cancer	0.000193	0.000678	CcSEcCtD
Clodronate—Anorexia—Capecitabine—kidney cancer	0.000191	0.000671	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—kidney cancer	0.000188	0.0012	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—BCHE—kidney cancer	0.000187	0.00119	CbGpPWpGaD
Clodronate—Vomiting—Gemcitabine—kidney cancer	0.000186	0.000651	CcSEcCtD
Clodronate—SLC25A5—Metabolism—SLC5A5—kidney cancer	0.000185	0.00118	CbGpPWpGaD
Clodronate—Rash—Gemcitabine—kidney cancer	0.000184	0.000646	CcSEcCtD
Clodronate—SLC25A4—Disease—ITPR2—kidney cancer	0.000184	0.00117	CbGpPWpGaD
Clodronate—Dermatitis—Gemcitabine—kidney cancer	0.000184	0.000645	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—IGF2—kidney cancer	0.000184	0.00117	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—GSTM1—kidney cancer	0.000184	0.00117	CbGpPWpGaD
Clodronate—Nausea—Vincristine—kidney cancer	0.000183	0.000641	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.000181	0.00115	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.000181	0.00115	CbGpPWpGaD
Clodronate—Pharyngitis—Doxorubicin—kidney cancer	0.000181	0.000634	CcSEcCtD
Clodronate—SLC25A6—Metabolism—ACHE—kidney cancer	0.00018	0.00115	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—GSTT1—kidney cancer	0.00018	0.00115	CbGpPWpGaD
Clodronate—Urinary tract disorder—Doxorubicin—kidney cancer	0.00018	0.00063	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—kidney cancer	0.000179	0.000627	CcSEcCtD
Clodronate—Dyspnoea—Capecitabine—kidney cancer	0.000179	0.000627	CcSEcCtD
Clodronate—SLC25A6—Disease—SLC2A1—kidney cancer	0.000179	0.00114	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—SLC2A1—kidney cancer	0.000178	0.00114	CbGpPWpGaD
Clodronate—Urethral disorder—Doxorubicin—kidney cancer	0.000178	0.000626	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—SOD2—kidney cancer	0.000178	0.00113	CbGpPWpGaD
Clodronate—SLC25A6—Disease—JUNB—kidney cancer	0.000177	0.00113	CbGpPWpGaD
Clodronate—Dyspepsia—Capecitabine—kidney cancer	0.000177	0.000619	CcSEcCtD
Clodronate—Decreased appetite—Capecitabine—kidney cancer	0.000174	0.000612	CcSEcCtD
Clodronate—Nausea—Gemcitabine—kidney cancer	0.000173	0.000608	CcSEcCtD
Clodronate—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000173	0.000607	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	0.000173	0.0011	CbGpPWpGaD
Clodronate—Pruritus—Paclitaxel—kidney cancer	0.000173	0.000607	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	0.000172	0.0011	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN2B—kidney cancer	0.000172	0.0011	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.000172	0.00109	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—SCARB1—kidney cancer	0.00017	0.00109	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGR1—kidney cancer	0.000169	0.00108	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS1—kidney cancer	0.000169	0.00108	CbGpPWpGaD
Clodronate—Diarrhoea—Paclitaxel—kidney cancer	0.000167	0.000587	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CRABP1—kidney cancer	0.000166	0.00106	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PSMD7—kidney cancer	0.000165	0.00105	CbGpPWpGaD
Clodronate—Mediastinal disorder—Doxorubicin—kidney cancer	0.000164	0.000575	CcSEcCtD
Clodronate—Urticaria—Capecitabine—kidney cancer	0.000159	0.000559	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	0.000159	0.00101	CbGpPWpGaD
Clodronate—Abdominal pain—Capecitabine—kidney cancer	0.000159	0.000556	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—POMC—kidney cancer	0.000157	0.001	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—BCHE—kidney cancer	0.000157	0.001	CbGpPWpGaD
Clodronate—Vomiting—Paclitaxel—kidney cancer	0.000155	0.000545	CcSEcCtD
Clodronate—SLC25A6—Metabolism—SLC5A5—kidney cancer	0.000155	0.000988	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PSMD7—kidney cancer	0.000154	0.000983	CbGpPWpGaD
Clodronate—Rash—Paclitaxel—kidney cancer	0.000154	0.000541	CcSEcCtD
Clodronate—SLC25A4—Metabolism—ITPR2—kidney cancer	0.000154	0.000982	CbGpPWpGaD
Clodronate—Dermatitis—Paclitaxel—kidney cancer	0.000154	0.00054	CcSEcCtD
Clodronate—SLC25A6—Metabolism—SLC2A1—kidney cancer	0.00015	0.000954	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.000149	0.000952	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—GSTP1—kidney cancer	0.000149	0.000949	CbGpPWpGaD
Clodronate—Anaemia—Doxorubicin—kidney cancer	0.000146	0.000514	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—kidney cancer	0.000145	0.000926	CbGpPWpGaD
Clodronate—Nausea—Paclitaxel—kidney cancer	0.000145	0.000509	CcSEcCtD
Clodronate—SLC25A6—Disease—CDKN2B—kidney cancer	0.000144	0.00092	CbGpPWpGaD
Clodronate—Pruritus—Capecitabine—kidney cancer	0.000142	0.000498	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—kidney cancer	0.000141	0.000901	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ABCB1—kidney cancer	0.000141	0.000899	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—GSTT1—kidney cancer	0.00014	0.000896	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ACHE—kidney cancer	0.00014	0.000896	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SLC2A1—kidney cancer	0.000139	0.000889	CbGpPWpGaD
Clodronate—SLC25A4—Disease—JUNB—kidney cancer	0.000138	0.000883	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HIF1A—kidney cancer	0.000138	0.000878	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TSC2—kidney cancer	0.000137	0.000876	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.000137	0.000875	CbGpPWpGaD
Clodronate—Diarrhoea—Capecitabine—kidney cancer	0.000137	0.000481	CcSEcCtD
Clodronate—SLC25A5—Metabolism—GSTM1—kidney cancer	0.000137	0.000872	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KIT—kidney cancer	0.000136	0.000869	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000134	0.000856	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000134	0.00047	CcSEcCtD
Clodronate—SLC25A4—Metabolism—SCARB1—kidney cancer	0.000133	0.000848	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	0.000132	0.000841	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS1—kidney cancer	0.000132	0.000839	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CYP1A1—kidney cancer	0.00013	0.000827	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PSMD7—kidney cancer	0.000129	0.000823	CbGpPWpGaD
Clodronate—Infection—Doxorubicin—kidney cancer	0.000128	0.000451	CcSEcCtD
Clodronate—Vomiting—Capecitabine—kidney cancer	0.000128	0.000447	CcSEcCtD
Clodronate—Rash—Capecitabine—kidney cancer	0.000126	0.000444	CcSEcCtD
Clodronate—Dermatitis—Capecitabine—kidney cancer	0.000126	0.000443	CcSEcCtD
Clodronate—Skin disorder—Doxorubicin—kidney cancer	0.000126	0.000441	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GSTP1—kidney cancer	0.000125	0.000795	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—kidney cancer	0.000124	0.000791	CbGpPWpGaD
Clodronate—Anorexia—Doxorubicin—kidney cancer	0.000123	0.000432	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.000123	0.000786	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.000123	0.000786	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—POMC—kidney cancer	0.000123	0.000783	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—BCHE—kidney cancer	0.000122	0.00078	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	0.000121	0.000774	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KIT—kidney cancer	0.000121	0.000773	CbGpPWpGaD
Clodronate—SLC25A5—Disease—APC—kidney cancer	0.000121	0.000773	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—SLC5A5—kidney cancer	0.000121	0.000771	CbGpPWpGaD
Clodronate—Nausea—Capecitabine—kidney cancer	0.000119	0.000418	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	0.000119	0.000757	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ABCB1—kidney cancer	0.000118	0.000753	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—SLC2A1—kidney cancer	0.000117	0.000745	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HIF1A—kidney cancer	0.000115	0.000736	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—kidney cancer	0.000115	0.000404	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	0.000115	0.000735	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TSC2—kidney cancer	0.000115	0.000734	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—GSTM1—kidney cancer	0.000115	0.000731	CbGpPWpGaD
Clodronate—SLC25A5—Disease—BRAF—kidney cancer	0.000114	0.000727	CbGpPWpGaD
Clodronate—Dyspepsia—Doxorubicin—kidney cancer	0.000114	0.000399	CcSEcCtD
Clodronate—SLC25A4—Disease—CDKN2B—kidney cancer	0.000113	0.000718	CbGpPWpGaD
Clodronate—Decreased appetite—Doxorubicin—kidney cancer	0.000112	0.000394	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—CTNNB1—kidney cancer	0.000112	0.000715	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	0.000112	0.000715	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000112	0.000392	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN2A—kidney cancer	0.000111	0.000706	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CYP1A1—kidney cancer	0.000109	0.000693	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CD4—kidney cancer	0.000104	0.000665	CbGpPWpGaD
Clodronate—Urticaria—Doxorubicin—kidney cancer	0.000103	0.00036	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—RELA—kidney cancer	0.000103	0.000654	CbGpPWpGaD
Clodronate—Abdominal pain—Doxorubicin—kidney cancer	0.000102	0.000359	CcSEcCtD
Clodronate—SLC25A6—Disease—APC—kidney cancer	0.000102	0.000648	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KIT—kidney cancer	0.000102	0.000648	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	0.000101	0.000645	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	0.0001	0.00064	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN1B—kidney cancer	9.8e-05	0.000625	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	9.8e-05	0.000625	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—GSTP1—kidney cancer	9.74e-05	0.000621	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—POMC—kidney cancer	9.67e-05	0.000617	CbGpPWpGaD
Clodronate—SLC25A6—Disease—BRAF—kidney cancer	9.55e-05	0.000609	CbGpPWpGaD
Clodronate—SLC25A5—Disease—RAF1—kidney cancer	9.52e-05	0.000607	CbGpPWpGaD
Clodronate—SLC25A5—Disease—ERBB2—kidney cancer	9.42e-05	0.000601	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CCND1—kidney cancer	9.35e-05	0.000596	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MTOR—kidney cancer	9.29e-05	0.000593	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CD4—kidney cancer	9.28e-05	0.000592	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ABCB1—kidney cancer	9.22e-05	0.000588	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTGS2—kidney cancer	9.21e-05	0.000587	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—kidney cancer	9.15e-05	0.000321	CcSEcCtD
Clodronate—SLC25A4—Disease—HIF1A—kidney cancer	9.01e-05	0.000574	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TSC2—kidney cancer	8.98e-05	0.000573	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—GSTM1—kidney cancer	8.95e-05	0.000571	CbGpPWpGaD
Clodronate—Diarrhoea—Doxorubicin—kidney cancer	8.85e-05	0.00031	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—CTNNB1—kidney cancer	8.76e-05	0.000559	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN1B—kidney cancer	8.72e-05	0.000556	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ACY1—kidney cancer	8.63e-05	0.00055	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CYP1A1—kidney cancer	8.48e-05	0.000541	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CTNNB1—kidney cancer	8.24e-05	0.000525	CbGpPWpGaD
Clodronate—PTGS2—Disease—CCBL1—kidney cancer	8.23e-05	0.000525	CbGpPWpGaD
Clodronate—Vomiting—Doxorubicin—kidney cancer	8.22e-05	0.000288	CcSEcCtD
Clodronate—Rash—Doxorubicin—kidney cancer	8.15e-05	0.000286	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—kidney cancer	8.14e-05	0.000286	CcSEcCtD
Clodronate—SLC25A6—Metabolism—POMC—kidney cancer	8.1e-05	0.000517	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTEN—kidney cancer	8.03e-05	0.000512	CbGpPWpGaD
Clodronate—SLC25A6—Disease—RAF1—kidney cancer	7.98e-05	0.000509	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KIT—kidney cancer	7.93e-05	0.000506	CbGpPWpGaD
Clodronate—SLC25A4—Disease—APC—kidney cancer	7.93e-05	0.000506	CbGpPWpGaD
Clodronate—SLC25A6—Disease—ERBB2—kidney cancer	7.89e-05	0.000503	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MTOR—kidney cancer	7.79e-05	0.000497	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD4—kidney cancer	7.77e-05	0.000496	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTGS2—kidney cancer	7.72e-05	0.000492	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—kidney cancer	7.71e-05	0.000492	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—kidney cancer	7.68e-05	0.000269	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—kidney cancer	7.5e-05	0.000478	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CDKN1B—kidney cancer	7.47e-05	0.000476	CbGpPWpGaD
Clodronate—SLC25A4—Disease—BRAF—kidney cancer	7.46e-05	0.000476	CbGpPWpGaD
Clodronate—PTGS2—Disease—AMER1—kidney cancer	7.45e-05	0.000475	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	7.36e-05	0.000469	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PDHB—kidney cancer	7.33e-05	0.000468	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1B—kidney cancer	7.31e-05	0.000466	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—kidney cancer	7.31e-05	0.000466	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—kidney cancer	7.12e-05	0.000454	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	7.06e-05	0.00045	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—kidney cancer	6.93e-05	0.000442	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CTNNB1—kidney cancer	6.9e-05	0.00044	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CCBL1—kidney cancer	6.9e-05	0.00044	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK3—kidney cancer	6.86e-05	0.000438	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTEN—kidney cancer	6.73e-05	0.000429	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTEN—kidney cancer	6.73e-05	0.000429	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—kidney cancer	6.67e-05	0.000426	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK1—kidney cancer	6.53e-05	0.000416	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—kidney cancer	6.46e-05	0.000412	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—POMC—kidney cancer	6.32e-05	0.000403	CbGpPWpGaD
Clodronate—PTGS2—Disease—GPC3—kidney cancer	6.24e-05	0.000398	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	6.24e-05	0.000398	CbGpPWpGaD
Clodronate—SLC25A4—Disease—RAF1—kidney cancer	6.23e-05	0.000397	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—kidney cancer	6.17e-05	0.000393	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ERBB2—kidney cancer	6.16e-05	0.000393	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MTOR—kidney cancer	6.08e-05	0.000388	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD4—kidney cancer	6.07e-05	0.000387	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—kidney cancer	6.02e-05	0.000384	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPAT—kidney cancer	5.98e-05	0.000381	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GLIPR1—kidney cancer	5.98e-05	0.000381	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	5.9e-05	0.000376	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK3—kidney cancer	5.87e-05	0.000375	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	5.84e-05	0.000373	CbGpPWpGaD
Clodronate—PTGS2—Disease—ST3GAL2—kidney cancer	5.77e-05	0.000368	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK3—kidney cancer	5.75e-05	0.000367	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—kidney cancer	5.71e-05	0.000364	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1B—kidney cancer	5.71e-05	0.000364	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CA—kidney cancer	5.66e-05	0.000361	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—kidney cancer	5.64e-05	0.000359	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—kidney cancer	5.59e-05	0.000357	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK1—kidney cancer	5.59e-05	0.000356	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—FH—kidney cancer	5.56e-05	0.000354	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—APRT—kidney cancer	5.56e-05	0.000354	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	5.54e-05	0.000354	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	5.48e-05	0.00035	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK1—kidney cancer	5.47e-05	0.000349	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	5.43e-05	0.000346	CbGpPWpGaD
Clodronate—PTGS2—Disease—PGK1—kidney cancer	5.41e-05	0.000345	CbGpPWpGaD
Clodronate—PTGS2—Disease—SLC5A3—kidney cancer	5.41e-05	0.000345	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—kidney cancer	5.39e-05	0.000344	CbGpPWpGaD
Clodronate—PTGS2—Disease—LDHB—kidney cancer	5.31e-05	0.000338	CbGpPWpGaD
Clodronate—PTGS2—Disease—SFRP2—kidney cancer	5.31e-05	0.000338	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—kidney cancer	5.25e-05	0.000335	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GPC3—kidney cancer	5.23e-05	0.000333	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—kidney cancer	5.17e-05	0.00033	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CA2—kidney cancer	5.08e-05	0.000324	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	5.08e-05	0.000324	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—kidney cancer	5.04e-05	0.000322	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ALAD—kidney cancer	4.95e-05	0.000316	CbGpPWpGaD
Clodronate—PTGS2—Disease—TCEB1—kidney cancer	4.95e-05	0.000316	CbGpPWpGaD
Clodronate—PTGS2—Disease—TCEB2—kidney cancer	4.95e-05	0.000316	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	4.85e-05	0.000309	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ST3GAL2—kidney cancer	4.84e-05	0.000308	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	4.84e-05	0.000308	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	4.8e-05	0.000306	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CA—kidney cancer	4.75e-05	0.000303	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CA—kidney cancer	4.74e-05	0.000303	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ALDH1A1—kidney cancer	4.73e-05	0.000301	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—kidney cancer	4.69e-05	0.000299	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	4.68e-05	0.000298	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC5A3—kidney cancer	4.53e-05	0.000289	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PGK1—kidney cancer	4.53e-05	0.000289	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK3—kidney cancer	4.49e-05	0.000286	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—LDHB—kidney cancer	4.44e-05	0.000283	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—kidney cancer	4.4e-05	0.000281	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—kidney cancer	4.37e-05	0.000278	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK1—kidney cancer	4.27e-05	0.000272	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	4.22e-05	0.000269	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—kidney cancer	4.03e-05	0.000257	CbGpPWpGaD
Clodronate—PTGS2—Disease—RPL14—kidney cancer	4.02e-05	0.000256	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4e-05	0.000255	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CA—kidney cancer	3.98e-05	0.000254	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	3.89e-05	0.000248	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CA9—kidney cancer	3.85e-05	0.000246	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	3.8e-05	0.000242	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.77e-05	0.00024	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CA—kidney cancer	3.71e-05	0.000236	CbGpPWpGaD
Clodronate—PTGS2—Disease—ITPR2—kidney cancer	3.64e-05	0.000232	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	3.59e-05	0.000229	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	3.3e-05	0.00021	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CRABP1—kidney cancer	3.28e-05	0.000209	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.19e-05	0.000204	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CA—kidney cancer	3.1e-05	0.000198	CbGpPWpGaD
Clodronate—PTGS2—Disease—PSMD7—kidney cancer	3.05e-05	0.000194	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ITPR2—kidney cancer	3.05e-05	0.000194	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.81e-05	0.000179	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTT1—kidney cancer	2.78e-05	0.000177	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ACHE—kidney cancer	2.78e-05	0.000177	CbGpPWpGaD
Clodronate—PTGS2—Disease—SLC2A1—kidney cancer	2.76e-05	0.000176	CbGpPWpGaD
Clodronate—PTGS2—Disease—JUNB—kidney cancer	2.74e-05	0.000174	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SCARB1—kidney cancer	2.63e-05	0.000168	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTGS1—kidney cancer	2.6e-05	0.000166	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PSMD7—kidney cancer	2.55e-05	0.000163	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—BCHE—kidney cancer	2.42e-05	0.000154	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC5A5—kidney cancer	2.39e-05	0.000152	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC2A1—kidney cancer	2.31e-05	0.000147	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN2B—kidney cancer	2.23e-05	0.000142	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.95e-05	0.000125	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTP1—kidney cancer	1.93e-05	0.000123	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ABCB1—kidney cancer	1.82e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Disease—HIF1A—kidney cancer	1.78e-05	0.000114	CbGpPWpGaD
Clodronate—PTGS2—Disease—TSC2—kidney cancer	1.78e-05	0.000113	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTM1—kidney cancer	1.77e-05	0.000113	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP1A1—kidney cancer	1.68e-05	0.000107	CbGpPWpGaD
Clodronate—PTGS2—Disease—KIT—kidney cancer	1.57e-05	0.0001	CbGpPWpGaD
Clodronate—PTGS2—Disease—APC—kidney cancer	1.57e-05	0.0001	CbGpPWpGaD
Clodronate—PTGS2—Disease—BRAF—kidney cancer	1.47e-05	9.4e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.38e-05	8.79e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—POMC—kidney cancer	1.25e-05	7.97e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—RAF1—kidney cancer	1.23e-05	7.85e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB2—kidney cancer	1.22e-05	7.77e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MTOR—kidney cancer	1.2e-05	7.66e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD4—kidney cancer	1.2e-05	7.65e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1B—kidney cancer	1.13e-05	7.19e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—kidney cancer	1.07e-05	6.8e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—kidney cancer	1.04e-05	6.62e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK3—kidney cancer	8.87e-06	5.66e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—kidney cancer	8.7e-06	5.55e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—kidney cancer	8.63e-06	5.5e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK1—kidney cancer	8.44e-06	5.38e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—kidney cancer	7.98e-06	5.09e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CA—kidney cancer	7.33e-06	4.67e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CA—kidney cancer	6.14e-06	3.91e-05	CbGpPWpGaD
